FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380591275> ?p ?o ?g. }

• W4380591275 endingPage "9047" @default.
• W4380591275 startingPage "9047" @default.
• W4380591275 abstract "9047 Background: NTRK fusions, encoding for constitutively active oncogenic tropomyosin receptor kinase proteins, are present in many solid tumors, including NSCLC. As central nervous system (CNS) metastases are common in pts with advanced NSCLC, treatments with intracranial efficacy are needed. Entrectinib, a potent CNS-active tyrosine kinase inhibitor, has previously demonstrated efficacy in pts with NTRK-fp NSCLC in an integrated analysis of three phase I/II trials (ALKA-372-001 [EudraCT, 2012-000148–88], STARTRK-1 [NCT02097810], STARTRK-2 [NCT02568267]); objective response rate (ORR) was 63.6% (14/22; data cutoff: August 31 2020). We present updated data for this cohort. Methods: Pts ≥18 years old with locally advanced/metastatic NTRK-fp tumors were enrolled and received 600 mg oral entrectinib until disease progression, toxicity, or death. At Week 4 and then every 8 weeks, tumour response was assessed by blinded independent central review (BICR) per RECIST v1.1. Co-primary endpoints were ORR and duration of response (DoR). Secondary endpoints included progression-free survival (PFS), overall survival (OS), intracranial efficacy, and safety. Enrolment cutoff: July 2 2020; data cutoff: August 2 2021. Results: The efficacy-evaluable population included 31 pts with NTRK-fp NSCLC. Median age was 60.0 years (range 22–88); 26 pts (83.9%) had adenocarcinoma; 11 pts (35.5%) had ≥2 prior lines of systemic therapy; 18 pts (58.1%) were current or former smokers; 15 pts (48.4%) had investigator-assessed baseline CNS metastases. Median survival follow up was 21.8 months (95% CI 19.5–30.2). Entrectinib treatment showed efficacy in pts with NTRK-fp NSCLC, including those with baseline CNS metastases by investigator (Table). In pts with BICR-assessed CNS metastases, intracranial ORR was 60.0% (6/10; 95% CI 26.2–87.8), median intracranial DoR was not estimable (NE), and median intracranial PFS was 8.9 months (95% CI 5.6–NE). In the safety-evaluable population (N=35), most treatment-related adverse events (TRAEs) were Grade 1–2 and non-serious. TRAEs led to dose reduction, interruption and discontinuation in 31.4%, 28.6%, and 5.7% of pts, respectively, and no treatment-related deaths occurred. Conclusions: In line with previously reported data, treatment with entrectinib was associated with deep and durable systemic and intracranial responses in pts with advanced NTRK-fp NSCLC. Clinical trial information: EUCTR 2012-000148-88 , NCT02097810 , NCT02568267 . [Table: see text]" @default.
• W4380591275 created "2023-06-15" @default.
• W4380591275 creator A5011751380 @default.
• W4380591275 creator A5028021994 @default.
• W4380591275 creator A5028935333 @default.
• W4380591275 creator A5037461196 @default.
• W4380591275 creator A5042877747 @default.
• W4380591275 creator A5045076272 @default.
• W4380591275 creator A5050461843 @default.
• W4380591275 creator A5052765312 @default.
• W4380591275 creator A5062173452 @default.
• W4380591275 creator A5064697305 @default.
• W4380591275 creator A5069918600 @default.
• W4380591275 creator A5088319794 @default.
• W4380591275 creator A5089757931 @default.
• W4380591275 creator A5090038152 @default.
• W4380591275 date "2023-06-01" @default.
• W4380591275 modified "2023-10-02" @default.
• W4380591275 title "Updated efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic <i>NTRK</i> fusion-positive (fp) non-small cell lung cancer (NSCLC)." @default.
• W4380591275 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.9047" @default.
• W4380591275 hasPublicationYear "2023" @default.
• W4380591275 type Work @default.
• W4380591275 citedByCount "0" @default.
• W4380591275 crossrefType "journal-article" @default.
• W4380591275 hasAuthorship W4380591275A5011751380 @default.
• W4380591275 hasAuthorship W4380591275A5028021994 @default.
• W4380591275 hasAuthorship W4380591275A5028935333 @default.
• W4380591275 hasAuthorship W4380591275A5037461196 @default.
• W4380591275 hasAuthorship W4380591275A5042877747 @default.
• W4380591275 hasAuthorship W4380591275A5045076272 @default.
• W4380591275 hasAuthorship W4380591275A5050461843 @default.
• W4380591275 hasAuthorship W4380591275A5052765312 @default.
• W4380591275 hasAuthorship W4380591275A5062173452 @default.
• W4380591275 hasAuthorship W4380591275A5064697305 @default.
• W4380591275 hasAuthorship W4380591275A5069918600 @default.
• W4380591275 hasAuthorship W4380591275A5088319794 @default.
• W4380591275 hasAuthorship W4380591275A5089757931 @default.
• W4380591275 hasAuthorship W4380591275A5090038152 @default.
• W4380591275 hasConcept C121608353 @default.
• W4380591275 hasConcept C126322002 @default.
• W4380591275 hasConcept C143998085 @default.
• W4380591275 hasConcept C203092338 @default.
• W4380591275 hasConcept C2908647359 @default.
• W4380591275 hasConcept C31760486 @default.
• W4380591275 hasConcept C535046627 @default.
• W4380591275 hasConcept C71924100 @default.
• W4380591275 hasConcept C99454951 @default.
• W4380591275 hasConceptScore W4380591275C121608353 @default.
• W4380591275 hasConceptScore W4380591275C126322002 @default.
• W4380591275 hasConceptScore W4380591275C143998085 @default.
• W4380591275 hasConceptScore W4380591275C203092338 @default.
• W4380591275 hasConceptScore W4380591275C2908647359 @default.
• W4380591275 hasConceptScore W4380591275C31760486 @default.
• W4380591275 hasConceptScore W4380591275C535046627 @default.
• W4380591275 hasConceptScore W4380591275C71924100 @default.
• W4380591275 hasConceptScore W4380591275C99454951 @default.
• W4380591275 hasIssue "16_suppl" @default.
• W4380591275 hasLocation W43805912751 @default.
• W4380591275 hasOpenAccess W4380591275 @default.
• W4380591275 hasPrimaryLocation W43805912751 @default.
• W4380591275 hasRelatedWork W1982194812 @default.
• W4380591275 hasRelatedWork W2014184213 @default.
• W4380591275 hasRelatedWork W2126237794 @default.
• W4380591275 hasRelatedWork W2126488520 @default.
• W4380591275 hasRelatedWork W2130626169 @default.
• W4380591275 hasRelatedWork W2169374891 @default.
• W4380591275 hasRelatedWork W2414965726 @default.
• W4380591275 hasRelatedWork W2886193299 @default.
• W4380591275 hasRelatedWork W3089163820 @default.
• W4380591275 hasRelatedWork W3177224496 @default.
• W4380591275 hasVolume "41" @default.
• W4380591275 isParatext "false" @default.
• W4380591275 isRetracted "false" @default.
• W4380591275 workType "article" @default.